DJIA 17,826.30 -279.47 -1.54%
NASDAQ 4,931.82 -75.98 -1.52%
S&P 500 2,081.18 -23.81 -1.13%
market minute promo

Gilead Sciences (NASDAQ: GILD)

101.38 -1.96 (-1.90%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

GILD $101.38 -1.90%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $102.35
Previous Close $103.34
Daily Range $100.61 - $102.81
52-Week Range $69.09 - $116.83
Market Cap $151.0B
P/E Ratio 14.06
Dividend (Yield) $0.00 (0.0%)
Volume 9,870,107
Average Daily Volume 10,790,102
Current FY EPS $10.18

Sector

Healthcare

Industry

Drug Makers

Gilead Sciences (GILD) Description

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide. Website: http://www.gilead.com/

News & Commentary

3 Drug Stocks Leading the Charge Against Infectious Diseases

Our experts weigh in.

Morningstar: Gilead Sciences To Grow Its Hepatitis C Market

These Companies Probably Won't Be Acquiring Ariad Pharmaceuticals

What Could Possibly Go Wrong With Gilead Sciences Inc. Stock?

Three risks for Gilead Sciences.

Gilead Sciences (GILD) Shares Cross Below 200 DMA

AbbVie's HCV Treatment Granted Priority Review in Japan - Analyst Blog

Healthcare ETFs in Focus Post JNJ Earnings Beat - ETF News And Commentary

Healthcare ETFs in Focus Post JNJ Earnings Beat - ETF News And Commentary

Gilead Is A Cash Generation Monster

Johnson & Johnson's Earnings: The Good, The Bad and The Ugly

Johnson & Johnson reported a mixed first-quarter this week. Here is what investors need to know going forward.

The Best Stock to Invest in Hep C

In the multibillion-dollar market for hepatitis C, this company stands above the crowd.

See More GILD News...

GILD's Top Competitors

GILD $101.38 (-1.90%)
Current stock: GILD
AMGN $163.58 (-1.97%)
Current stock: AMGN
CELG $113.47 (-2.48%)
Current stock: CELG
$0.00 (0.00%)
Current stock: